Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGT-61159 in adults with sickle cell disease
PACTR202610488237902Phase 1Not yet recruiting
- Sponsor
- Rgenta Therapeutics
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGT-61159 in sickle cell disease (SCD) (3 arms), sponsored by Rgenta Therapeutics. Primary endpoints: Safety and tolerability of multiple doses of RGT-61159 and Early fetal hemoglobin induction at Day 28. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
RGT-61159
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202610488237902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610488237902.